Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) rose 8.7% during trading on Friday . The company traded as high as $8.38 and last traded at $8.24. Approximately 3,353,225 shares changed hands during trading, an increase of 22% from the average daily volume of 2,739,171 shares. The stock had previously closed at $7.58.
Wall Street Analyst Weigh In
NTLA has been the topic of a number of research analyst reports. Barclays dropped their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Intellia Therapeutics in a report on Thursday, May 29th. Chardan Capital reaffirmed a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a research report on Friday, May 9th. Wells Fargo & Company decreased their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $34.95.
Get Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Stock Performance
The business has a 50 day simple moving average of $7.95 and a 200-day simple moving average of $9.97. The stock has a market cap of $857.67 million, a P/E ratio of -1.52 and a beta of 2.14.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. The firm's revenue for the quarter was down 42.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.12) EPS. On average, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Intellia Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock valued at $3,709,000 after acquiring an additional 38,521 shares in the last quarter. Woodline Partners LP purchased a new stake in shares of Intellia Therapeutics in the 1st quarter worth $171,000. Arete Wealth Advisors LLC increased its stake in shares of Intellia Therapeutics by 21.8% in the 1st quarter. Arete Wealth Advisors LLC now owns 12,512 shares of the company's stock worth $89,000 after purchasing an additional 2,240 shares in the last quarter. Granahan Investment Management LLC increased its holdings in Intellia Therapeutics by 55.3% in the 1st quarter. Granahan Investment Management LLC now owns 475,946 shares of the company's stock worth $3,384,000 after acquiring an additional 169,436 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company's stock worth $646,000 after buying an additional 55,118 shares in the last quarter. Institutional investors own 88.77% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Articles
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
